Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 138

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 138
---
 Purchaser, if: |

| a. | a breach of any representation or warranty or failure to perform any covenant or agreement on the part of the                                                                                                                                           
 Company under the Agreement occurs that would cause certain conditions relating to representations and warranties of the Company or performance of covenants by the Company not to be satisfied, and such breach or failure is incapable of being cured 
 or is not cured; provided that the Purchaser is not then in breach of the Agreement so as to directly or indirectly cause conditions related to representations and warranties of the Purchaser and performance of covenants by the Purchaser not to be 
 satisfied;                                                                                                                                                                                                                                              |

| a. | if the Board or the Transaction Committee (1)(I) withholds or withdraws (or amends, modifies or qualifies in a                                                                                                                                            
 manner adverse to Parent or the Purchaser) the Board Recommendation, or proposes publicly to withhold or withdraw (or amend, modify or qualify in a manner adverse to Parent or the Purchaser) the Board Recommendation or fails to publicly reaffirm the 
 Board Recommendation within five (5) Business Days after having been requested in writing by the Purchaser to do so (or in the event that the Special Meeting is scheduled to occur within such five Business Day period, prior to the third              
 Business Day prior to the date of the Special Meeting), or (II) withholds or withdraws (or amends, modifies or qualifies in a manner adverse to Parent or the Purchaser) or proposes publicly to withhold or withdraw (or amend, modify or qualify        
 in a manner adverse to Parent or the Purchaser) any of the recommendations of the Transaction Committee referred to in Paragraph 43(a) of Schedule E of the Agreement, respectively, (2) accepts, approves, endorses or recommends, or publicly           
 proposes to accept, approve, endorse or recommend an Acquisition Proposal, or (3) takes no position or a neutral position with respect to an Acquisition Proposal for more than five (5) Business Days after the public announcement of such              
 Acquisition Proposal (or beyond the third Business Day prior to the date of the Special Meeting, if sooner), or (4) the Board or any committee of the Board accepts, approves, endorses, recommends or authorizes the Company to enter into a             
 written agreement concerning a Superior Proposal;                                                                                                                                                                                                         |

| c. | there has occurred a Material Adverse Change after the date of the Agreement; |

| d. | the Company breaches any covenant or obligation relating to               
 non-solicitation obligations under